CD274 and neoplasm: To validate our approach, we examined the anti-tumor efficacy of SC144@HABN + anti-PD-L1 ICB therapy in BALB/c mice bearing 4T1 tumor, which is an aggressive breast cancer model that is resistant to anti-PD-L1 and other ICB therapies22.